
Medtronic (MDT) Stock Forecast & Price Target
Medtronic (MDT) Analyst Ratings
Bulls say
Medtronic is a leading medical device company with a strong product pipeline that is expected to drive revenue growth and margin improvement. However, inconsistent execution and quarterly results may limit the company's potential for P/E multiple expansion. Upside drivers include better than expected sales of new products, better margins, and positive currency impacts. Risks include loss of market share to competitors and disappointing sales from new products. With the recent acquisition of Scientia Vascular, Medtronic may be poised for significant earnings growth in the future.
Bears say
Medtronic is expected to face risks such as market share loss to competitors, underwhelming sales from new products and negative currency impacts. The company's bear case scenario includes a growth slowdown of <5% due to unsuccessful new product launches and market share loss, resulting in a below-consensus earnings that corresponds to ~$76 per share. In contrast, the base case scenario predicts revenue growth in the range of 5-7%, driven by the company's new product pipeline and improved operating margins, resulting in moderately above-consensus earnings. However, there are still risks to the company's target, including market share loss to competitors, underwhelming sales from new products and negative currency impacts.
This aggregate rating is based on analysts' research of Medtronic and is not a guaranteed prediction by Public.com or investment advice.
Medtronic (MDT) Analyst Forecast & Price Prediction
Start investing in Medtronic (MDT)
Order type
Buy in
Order amount
Est. shares
0 shares